|Bid||114.00 x 100|
|Ask||116.40 x 200|
|Day's Range||110.60 - 118.40|
|52 Week Range||31.38 - 118.40|
|PE Ratio (TTM)||-22.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Why Madrigal, Alnylam, and Arbutus Biopharma stocks were this week's biggest biotech winners.
Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.
Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.